<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23029378</PMID><DateCompleted><Year>2013</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>9</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Comparative analysis of the immunogenicity and protective effects of inactivated EV71 vaccines in mice.</ArticleTitle><Pagination><StartPage>e46043</StartPage><MedlinePgn>e46043</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e46043</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0046043</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Enterovirus 71 (EV71) is the major causative agent of hand, foot, and mouth disease (HFMD). Three inactivated EV71 whole-virus vaccines of different strains developed by different manufacturers in mainland China have recently entered clinical trials. Although several studies on these vaccines have been published, a study directly comparing the immunogenicity and protective effects among them has not been carried out, which makes evaluating their relative effectiveness difficult. Thus, properly comparing newly developed vaccines has become a priority, especially in China.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">This comparative immunogenicity study was carried out on vaccine strains (both live and inactivated), final container products (FCPs) without adjuvant, and corresponding FCPs containing adjuvant (FCP-As) produced by three manufacturers. These vaccines were evaluated by neutralizing antibody (NAb) responses induced by the same or different dosages at one or multiple time points post-immunization. The protective efficacy of the three vaccines was also determined in one-day-old ICR mice born to immunized female mice. Survival rates were observed in these suckling mice after challenge with 20 LD(50) of EV71/048M3C2. Three FCP-As, in a dose of 200 U, generated nearly 100% NAb positivity rates and similar geometric mean titers (GMTs), especially at 14-21 days post-inoculation. However, the dynamic NAb responses were different among three vaccine strains or three FCPs. The FCP-As at the lowest dose used in clinical trials (162 U) showed good protective effects in suckling mice against lethal challenge (90-100% survival), while the ED(50) of NAb responses and protective effects varied among three FCP-As.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These studies establish a standard method for measuring the immunogenicity of EV71 vaccines in mice. The data generated from our mouse model study indicated a clear dose-response relationship, which is important for vaccine quality control and assessment, especially for predicting protective efficacy in humans when combined with future clinical trial results.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Chenghong</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiuling</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Zengbing</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yiping</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Fengxiang</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Miao</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Weidong</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qihan</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Xinliang</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Junzhi</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>Q Gao and WD Yin are affiliated to Sinovac Biotech Co., Ltd. ZB Guo is affiliated to Hualan Biological Engineering Inc.; XL Li and XL Shen are affiliated to National Vaccine and Serum Institute; CH Dong and QH Li are affiliated to Institute of Medical Biology, Chinese Academy of Medical Sciences. As a Board member, WD Yin holds shares of Sinovac Biotech Co., Ltd. There are EV71 vaccines in development to declare. There are no consultancies, patents, or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies concerning sharing data and materials as detailed online in the guide for authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23029378</ArticleId><ArticleId IdType="pmc">PMC3460965</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0046043</ArticleId><ArticleId IdType="pii">PONE-D-12-16093</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, et al. (2010) Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10: 778&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L, Lu J, Kung HF, He ML (2011) The virology and developments toward control of human enterovirus 71. Crit Rev Microbiol 37: 313&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">21651436</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC (2002) An overview of the evolution of enterovirus 71 and its clinical and public health signifi cance. FEMS Microbiol Rev 26: 91&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SC, Chang HL, Yan TR, Cheng YT, Chen KT (2007) An eight-year study of epidemiologic features of enterovirus 71 infection in Taiwan. Am J Trop Med Hyg 77: 188&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">17620652</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health of the People's Republic of China website. Available: http://www.moh.gov.cn/publicfiles/business/htmlfiles/wsb/pyqxx/list.htm. Accessed 2012 Aug 30.</Citation></Reference><Reference><Citation>Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, et al. (2000) Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis 31: 678&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">11017815</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu PV, Thao NT, Perera D, Huu TK, Tien NT, et al. (2007) Epidemiologic and virologic investigation of hand, foot, and mouth disease, Southern Vietnam, 2005. Emerg Infect Dis 13: 1733&#x2013;1741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375788</ArticleId><ArticleId IdType="pubmed">18217559</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X, Huang X, Zhu S, Chen H, Yu Q, et al. (2011) The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS One 6: e25662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181342</ArticleId><ArticleId IdType="pubmed">21980521</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KH (2010) Enterovirus 71 infection: An experience in Korea, 2009. Korean J Pediatr 53: 616&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2994121</ArticleId><ArticleId IdType="pubmed">21189926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma E, Lam T, Chan KC, Wong C, Chuang SK (2010) Changing epidemiology of hand, foot, and mouth disease in Hong Kong, 2001&#x2013;2009. Jpn J Infect Dis 63: 422&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">21099093</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuta K, Abiko C, Murata T, Matsuzaki Y, Itagaki T, et al. (2005) Frequent importation of enterovirus 71 from surrounding countries into the local community of Yamagata, Japan, between1998 and 2003. J Clin Microbiol 43: 6171&#x2013;6175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1317214</ArticleId><ArticleId IdType="pubmed">16333123</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua KB, Kasri AR (2011) Hand Foot and Mouth Disease Due to Enterovirus 71 in Malaysia. Virol Sin 26: 221&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8222466</ArticleId><ArticleId IdType="pubmed">21847753</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Ho TS, Lin HC, Lei HY, Wang JR, et al. (2012) Reemerging of enterovirus 71 in Taiwan: the age impact on disease severity. Eur J Clin Microbiol Infect Dis 31: 1219&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pubmed">21983920</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, et al. (2007) An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 81: 9386&#x2013;9395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1951441</ArticleId><ArticleId IdType="pubmed">17567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Lian WC, Butler M, Wu SC (2007) High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine 25: 19&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16919374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, Devi S, Cardosa MJ, Wong KT (2010) Formadehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 84: 661&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798416</ArticleId><ArticleId IdType="pubmed">19864378</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HF, Chang MH, Chiang BL, Jeng ST (2006) Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 24: 2944&#x2013;2951.</Citation><ArticleIdList><ArticleId IdType="pubmed">16448730</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, et al. (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26: 1855&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung W, Bakar SA, Sekawi Z, Rosli R (2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genetic vaccines and therapy 5: 6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu CH, Chu C, He CC, Lin TY (2006) Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes and Infection 8: 1671&#x2013;1678.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815726</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivasamugham LA, Cardosa MJ, Tan WS, Yusoff K (2006) Recombinant Newcastle Disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits. Journal of Medical Virology 78: 1096&#x2013;1104.</Citation><ArticleIdList><ArticleId IdType="pubmed">16789020</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, et al. (2001) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20: 895&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, et al. (2012) Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: A randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 30 22 3295&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Trials website. Available: http://clinicaltrials.gov/ct2/show/NCT01268787?term=NCT01268787&amp;rank=1. Accessed 2012 Aug 30.</Citation></Reference><Reference><Citation>Clinical Trials website. Available: http://clinicaltrials.gov/ct2/show/NCT01376479?term=NCT01376479&amp;rank=1. Accessed 2012 Aug 30.</Citation></Reference><Reference><Citation>Mao QY, Li N, Yu X, Yao X, Li FX, et al. (2011) Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol 157: 37&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">21984267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, et al. (2011) Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 29: 4829&#x2013;4838.</Citation><ArticleIdList><ArticleId IdType="pubmed">21550375</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Liu L, Zhao H, Wang J, Liao Y, et al. (2011) Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 29: 6269&#x2013;6275.</Citation><ArticleIdList><ArticleId IdType="pubmed">21722686</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia H, Cai F, Gao Q, Zhang JS, Jing SR (2010) Development of A Quantitative ELISA Method for EV71 Antigen. Chin J Biologicals 23: 87&#x2013;90.</Citation></Reference><Reference><Citation>Liang ZL, Mao QY, Gao Q, Li XL, Dong CH, et al. (2011) Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 29: 9668&#x2013;9674.</Citation><ArticleIdList><ArticleId IdType="pubmed">22015395</ArticleId></ArticleIdList></Reference><Reference><Citation>Grandien M, Fosgren M, Ehrnet A (1995) Enterovirua. In: Lennette EH, Lennette DA, Lennette ET, editors. Diagnostic procedures for Viral, Rickettsial and Chlamydial Infections. 7th ed. Washington, DC: American Public Health Association. pp. 279&#x2013;298.</Citation></Reference><Reference><Citation>Mao QY, He P, Yu X, Li N, Hao CS (2010) Laboratory Evaluation of Method for Determination of Neutralizing Antibody against Human Enterovirus 71. Chin J Biologicals 23: 885&#x2013;888.</Citation></Reference><Reference><Citation>Manual for the virological investigation of polio. Available: http://whqlibdoc.who.int/hq/1997/WHO_EPI_GEN_97.01.pdf. Accessed 2007 Nov 25.</Citation></Reference><Reference><Citation>Martin A Hamilton (1979) Robust estimates of the ED50. Journal of the American Statistical Association 74: 344&#x2013;354.</Citation></Reference><Reference><Citation>Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, et al. (2000) Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 7: 523&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060501</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, et al. (2002) Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 109: e88&#x2013;e93.</Citation><ArticleIdList><ArticleId IdType="pubmed">12042582</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Chang LY (2010) Development of enterovirus 71 vaccines. Exerpt Rev. Vaccines 9: 149&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">20109026</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, Yang ZW, Yu X, Jing Q, He P, et al. (2009) Epidemic Tendency of Neutralizing Antibody against Enterovirus 71 and Coxsackievirus A 16 in Infants in Rural Area of Kaifeng City, Henan Province, China. Chin J Biologicals 22: 911&#x2013;913.</Citation></Reference><Reference><Citation>Liu CC, Chang HW, Yang G, Chiang JR, Chow YH, et al. (2011) Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process. J Virol Methods 176: 60&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">21704080</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LC, Tang SQ, Li YM, Zhao HL, Dong CH, et al. (2010) A Comparison of the Biological Characteristics of EV71 C4 Subtypes from Different Epidemic Strains. Virol Sin 25: 98&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8227828</ArticleId><ArticleId IdType="pubmed">20960306</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JY, Chang CP, Tsai HH, Lee CD, Lian WC, et al. (2012) Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. Vaccine 30: 703&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">22142585</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, et al. (2011) Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 29: 4362&#x2013;4372.</Citation><ArticleIdList><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>White JL, Hem SL (2000) Characterization of aluminum-containing adjuvants. In Brown F, Corbel M, Griffiths E, eds. Physico-Chemical procedures for the Characterization of vaccines. Basel, karger. pp. 217&#x2013;228.</Citation></Reference><Reference><Citation>Shirodkar S, Hutchinson RL, Perry DL, White JL, Hem SL (1990) Aluminum compounds used as adjuvants in vaccines. Pharm Res 7: 1282&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">2095567</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>